TABLE 2.

Levels of serum biomarkers associated with inflammation and thrombosis in critical and non-critical COVID-19 patients.

	All (n = 19)	Non-critical (n = 13)	Critical (n = 6)	P-value
Duration from infection to sample collection (days)	7 (5–11)	8 (6–12.5)	13 (11–13.3)	0.09
IL-18, pg/ml	402.0 ± 133.52	399.8 ± 133.4	406.8 ± 146.3	0.92
TNF-α, pg/ml	9.37 (7.93, 11.53)	9.4 (7.57, 13.16)	9.2 (8.29, 12.98)	0.76
VEGF, pg/ml	402.9 (266.7, 787.0)	382.1 (223.7, 519.3)	1133.7 (378.2, 1678.3)	0.11
IL-6, pg/ml	12.4 (4.96, 77.15)	10.5 (4.36, 19.05)	93.2 (12.6, 2285)	0.03
ADAMTS13, ng/ml	749.7 ± 135.88	762.1 ± 139.2	722.7 ± 136.7	0.57
ICAM-1, ng/ml	224.3 ± 84.3	202.9 ± 76.92	270.6 ± 87.36	0.11
LRG, μg/ml	22.7 ± 12.2	22.9 ± 12.6	22.1 ± 12.4	0.90

Data are expressed as the mean ± SD for normally distributed data or the median (interquartile range) for non-normally distributed data. Statistical analysis was performed by using unpaired Student t-test and Wilcoxon rank-sum test. Non-critical and Critical groups were included in this comparison. Statistical significance was accepted as P < 0.05. Data in bold are statistically significant. IL, interleukin; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor; ADAMTS13, a disintegrin, and metalloproteinase with thrombospondin type 1 motif member 13; ICAM-1, intercellular adhesion molecule-1; LRG, leucine-rich α-2-glycoprotein.